MEK inhibition in BRAF-mutated melanoma [1]

New England Journal of Medicine

Volumn 367, Issue 14, 2012, Pages 1364-1365

  Ascierto, Paolo A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

BRAF GENE; CANCER CHEMOTHERAPY; DRUG RESPONSE; GENE; GENE MUTATION; HUMAN; LETTER; MELANOMA; METASTATIC MELANOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; DRUG ANTAGONISM; FEMALE; GENETICS; MALE; NOTE;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES;

EID: 84867182097     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1209663     Document Type: Letter

References (5)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
2. Hauschild A, Grob JJ, Demidov LV, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF V600E-mutated melanoma. J Clin Oncol 2012;30:Suppl. abstract.
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
4. Trefzer U, Minor D, Ribas A, et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell Melanoma Res 2011;24:1020. abstract.
5. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.